We are so excited to have recently opened a 3,750 square foot research lab on the BCIT campus in Burnaby. This lab is crucial in our quest to help patients worldwide.
As a company we are committed to developing economical non-addictive prescription medications derived from specific cannabinoid molecules. Our core products target key disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology. This lab is our first step in fulfilling our dreams.
This is just the beginning! We are looking at a further expansion of 2,850 square feet at the end of Q2 2018. With this expansion, we will further develop our molecular research and eventually grow the facility into a GMP site for early-stage drug production.
Take a look at these highlights from our grand opening!